Pharmacokinetics and safety of trovafloxacin (CP-99, 219), a new quinolone antibiotic, following adminstration of single oral doses to healthy male volunteers

Renli Teng, Stephen C. Harris, David E. Nix, Jerome J. Schentag, George Foulds, Theodore E. Liston

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Trovafloxacin (CP-99, 219) is a new fluoroquinolone antibacterial agent with a broad spectrum of activity against Gram-positive and Gram-negative bacteria. The pharmacokinetics and safety of trovafloxacin were characterised in healthy male volunteers after administration of single oral doses of 30, 100, 300, 600 and 1000 mg. trovafloxacin was rapidly absorbed and serum concentrations reached a maximum approximately 1 h after dosing. The corresponding mean Cmax values (mean ± SD) were 0.3 ± 0.0, 1.5 ± 0.5, 4.4 ± 11, 6.6 ± 1.4 and 10.1 ± 0.5 mg/L. Terminal-phase half-life was independent of dose, with an overall mean of 9.9 ± 2.5 h. Generally, Cmax and AUC0∞ increased linearly with dose. Less than 10% of the administered dose was recovered unchanged in urine. Over the dosing range, trovafloxacin renal clearance was fairly constant, averaging 0.67 ± 0.36 L/h. Trovafloxacin binding to serum proteins was moderate (70%). Trovafloxacin was well tolerated at doses of 300 mg or below. There were no significant changes in the clinical chemistry or haematology parameters evaluated over the entire dosing range.

Original languageEnglish (US)
Pages (from-to)385-394
Number of pages10
JournalJournal of Antimicrobial Chemotherapy
Volume36
Issue number2
DOIs
StatePublished - Aug 1995
Externally publishedYes

Fingerprint

Bactericides
Pharmacokinetics
Quinolones
Antibiotics
Dose
Bacteria
Healthy Volunteers
Safety
Anti-Bacterial Agents
Proteins
Clearance
Mean Value
Range of data
Chemistry
Averaging
Clinical Chemistry
Fluoroquinolones
Linearly
Hematology
trovafloxacin

ASJC Scopus subject areas

  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Physiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)
  • Pharmacology
  • Microbiology

Cite this

Pharmacokinetics and safety of trovafloxacin (CP-99, 219), a new quinolone antibiotic, following adminstration of single oral doses to healthy male volunteers. / Teng, Renli; Harris, Stephen C.; Nix, David E.; Schentag, Jerome J.; Foulds, George; Liston, Theodore E.

In: Journal of Antimicrobial Chemotherapy, Vol. 36, No. 2, 08.1995, p. 385-394.

Research output: Contribution to journalArticle

@article{a2a7282449fc425e861cd2be21810a52,
title = "Pharmacokinetics and safety of trovafloxacin (CP-99, 219), a new quinolone antibiotic, following adminstration of single oral doses to healthy male volunteers",
abstract = "Trovafloxacin (CP-99, 219) is a new fluoroquinolone antibacterial agent with a broad spectrum of activity against Gram-positive and Gram-negative bacteria. The pharmacokinetics and safety of trovafloxacin were characterised in healthy male volunteers after administration of single oral doses of 30, 100, 300, 600 and 1000 mg. trovafloxacin was rapidly absorbed and serum concentrations reached a maximum approximately 1 h after dosing. The corresponding mean Cmax values (mean ± SD) were 0.3 ± 0.0, 1.5 ± 0.5, 4.4 ± 11, 6.6 ± 1.4 and 10.1 ± 0.5 mg/L. Terminal-phase half-life was independent of dose, with an overall mean of 9.9 ± 2.5 h. Generally, Cmax and AUC0∞ increased linearly with dose. Less than 10{\%} of the administered dose was recovered unchanged in urine. Over the dosing range, trovafloxacin renal clearance was fairly constant, averaging 0.67 ± 0.36 L/h. Trovafloxacin binding to serum proteins was moderate (70{\%}). Trovafloxacin was well tolerated at doses of 300 mg or below. There were no significant changes in the clinical chemistry or haematology parameters evaluated over the entire dosing range.",
author = "Renli Teng and Harris, {Stephen C.} and Nix, {David E.} and Schentag, {Jerome J.} and George Foulds and Liston, {Theodore E.}",
year = "1995",
month = "8",
doi = "10.1093/jac/36.2.385",
language = "English (US)",
volume = "36",
pages = "385--394",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics and safety of trovafloxacin (CP-99, 219), a new quinolone antibiotic, following adminstration of single oral doses to healthy male volunteers

AU - Teng, Renli

AU - Harris, Stephen C.

AU - Nix, David E.

AU - Schentag, Jerome J.

AU - Foulds, George

AU - Liston, Theodore E.

PY - 1995/8

Y1 - 1995/8

N2 - Trovafloxacin (CP-99, 219) is a new fluoroquinolone antibacterial agent with a broad spectrum of activity against Gram-positive and Gram-negative bacteria. The pharmacokinetics and safety of trovafloxacin were characterised in healthy male volunteers after administration of single oral doses of 30, 100, 300, 600 and 1000 mg. trovafloxacin was rapidly absorbed and serum concentrations reached a maximum approximately 1 h after dosing. The corresponding mean Cmax values (mean ± SD) were 0.3 ± 0.0, 1.5 ± 0.5, 4.4 ± 11, 6.6 ± 1.4 and 10.1 ± 0.5 mg/L. Terminal-phase half-life was independent of dose, with an overall mean of 9.9 ± 2.5 h. Generally, Cmax and AUC0∞ increased linearly with dose. Less than 10% of the administered dose was recovered unchanged in urine. Over the dosing range, trovafloxacin renal clearance was fairly constant, averaging 0.67 ± 0.36 L/h. Trovafloxacin binding to serum proteins was moderate (70%). Trovafloxacin was well tolerated at doses of 300 mg or below. There were no significant changes in the clinical chemistry or haematology parameters evaluated over the entire dosing range.

AB - Trovafloxacin (CP-99, 219) is a new fluoroquinolone antibacterial agent with a broad spectrum of activity against Gram-positive and Gram-negative bacteria. The pharmacokinetics and safety of trovafloxacin were characterised in healthy male volunteers after administration of single oral doses of 30, 100, 300, 600 and 1000 mg. trovafloxacin was rapidly absorbed and serum concentrations reached a maximum approximately 1 h after dosing. The corresponding mean Cmax values (mean ± SD) were 0.3 ± 0.0, 1.5 ± 0.5, 4.4 ± 11, 6.6 ± 1.4 and 10.1 ± 0.5 mg/L. Terminal-phase half-life was independent of dose, with an overall mean of 9.9 ± 2.5 h. Generally, Cmax and AUC0∞ increased linearly with dose. Less than 10% of the administered dose was recovered unchanged in urine. Over the dosing range, trovafloxacin renal clearance was fairly constant, averaging 0.67 ± 0.36 L/h. Trovafloxacin binding to serum proteins was moderate (70%). Trovafloxacin was well tolerated at doses of 300 mg or below. There were no significant changes in the clinical chemistry or haematology parameters evaluated over the entire dosing range.

UR - http://www.scopus.com/inward/record.url?scp=0029092852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029092852&partnerID=8YFLogxK

U2 - 10.1093/jac/36.2.385

DO - 10.1093/jac/36.2.385

M3 - Article

C2 - 8522468

AN - SCOPUS:0029092852

VL - 36

SP - 385

EP - 394

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 2

ER -